Get the Stockscreener App
46.86
0.02%
-0.010
Springworks Therapeutics Inc stock is traded at $46.86, with a volume of 4.19M.
It is down -0.02% in the last 24 hours and up +1.63% over the past month.
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.
See More
Previous Close:
$46.87
Open:
$46.85
24h Volume:
4.19M
Relative Volume:
0.82
Market Cap:
$3.52B
Revenue:
-
Net Income/Loss:
$-275.16M
P/E Ratio:
-12.05
EPS:
-3.89
Net Cash Flow:
$-221.15M
1W Performance:
+0.26%
1M Performance:
+1.63%
6M Performance:
+24.23%
1Y Performance:
+27.79%
1-Day Range:
$46.82
$46.90
1-Week Range:
$46.71
$46.92
52-Week Range:
$28.21
$62.00
Springworks Therapeutics Inc Stock (SWTX) Company Profile
Name
Springworks Therapeutics Inc
Sector
Industry
Phone
203-883-9490
Address
100 WASHINGTON BOULEVARD, STAMFORD, CT
Compare SWTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SWTX
Springworks Therapeutics Inc
|
46.86 | 3.52B | 0 | -275.16M | -221.15M | -3.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Springworks Therapeutics Inc Stock (SWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-24 | Initiated | Evercore ISI | Outperform |
| Feb-05-24 | Initiated | Guggenheim | Buy |
| Dec-01-22 | Initiated | BofA Securities | Buy |
| Jan-19-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Reiterated | H.C. Wainwright | Buy |
| May-05-20 | Initiated | Barclays | Overweight |
| Mar-19-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-04-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-04-19 | Initiated | H.C. Wainwright | Buy |
| Oct-08-19 | Initiated | Cowen | Outperform |
| Oct-08-19 | Initiated | Goldman | Buy |
| Oct-08-19 | Initiated | JP Morgan | Overweight |
| Oct-08-19 | Initiated | Wedbush | Outperform |
View All
Springworks Therapeutics Inc Stock (SWTX) Latest News
Assenagon Asset Management S.A. Takes Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
(SWTX) Technical Pivots with Risk Controls - news.stocktradersdaily.com
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
SpringWorks Therapeutics (SWTX) Continues Strong Yearly Run, Showing Over 29% YTD Gain - Daily Chhattisgarh News
Biotech Stocks To ConsiderJune 16th - MarketBeat
SpringWorks Therapeutics (NASDAQ:SWTX) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
FNY Investment Advisers LLC Purchases New Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics Announces Merger with Merck KGaA - TipRanks
SpringWorks Merger Moves Forward with Regulatory Clearances By Investing.com - Investing.com India
SpringWorks Merger Moves Forward with Regulatory Clearances - Investing.com
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates OPOF, PRA, SWTX, FLS on Behalf of Shareholders - ACCESS Newswire
HAPPY FATHER’S DAY and $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger: OPOF, PRA, SWTX and FLS - ACCESS Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPOF, PRA, SWTX on Behalf of Shareholders - GlobeNewswire Inc.
SpringWorks Therapeutics’ SWOT analysis: stock outlook amid Merck acquisition - Investing.com
SpringWorks Therapeutics (NASDAQ:SWTX) Sees Large Volume IncreaseShould You Buy? - MarketBeat
SpringWorks Therapeutics, Inc. Stock Update: Steady Performance Amid Market Trends - Daily Chhattisgarh News
Best Biotech Stocks To Research – June 9th - Defense World
Best Growth Stocks To Follow Now – June 9th - Defense World
Squarepoint Ops LLC Cuts Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
88,995 Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Bought by RFG Advisory LLC - MarketBeat
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Top Growth Stocks To Follow Now – June 4th - Defense World
Best Biotech Stocks Worth Watching – June 4th - Defense World
(SWTX) Proactive Strategies - news.stocktradersdaily.com
SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc.SWTX - Business Wire
Nuveen Asset Management LLC Has $6.64 Million Stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
$HAREHOLDER NOTICE: The M&A Class Action Firm Continues To Investigate The Merger - Benzinga
BNP Paribas Financial Markets Acquires Shares of 9,719 SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Promising Growth Stocks To Research – May 28th - Defense World
ProShare Advisors LLC Acquires 5,503 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Deutsche Bank AG Purchases 19,540 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Merck, SpringWorks receive German antitrust approval for their deal - MLex
Palisades Investment Partners LLC Purchases 12,154 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Bank of America Corp DE Reduces Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics (SWTX) Surged on Acquisition News - Insider Monkey
BNP Paribas Financial Markets Makes New $351,000 Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease - Nasdaq
SpringWorks Gets CHMP Nod For Mirdametinib In Rare Disease - Barchart.com
142,300 Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Bought by Zimmer Partners LP - MarketBeat
SpringWorks Therapeutics’ SWOT analysis: biotech stock faces acquisition challenges - Investing.com
Growth Stocks To Consider – May 23rd - Defense World
Growth Stocks To ConsiderMay 23rd - MarketBeat
(SWTX) Investment Analysis - news.stocktradersdaily.com
SpringWorks Therapeutics receives positive CHMP opinion for Mirdametinib for the treatment of adult and paediatric patients with NF1-PN | Health & Wellbeing | Lifestyle - The Phoenix Newspaper UK
SpringWorks Therapeutics (NASDAQ:SWTX) Sees Large Volume Increase – Time to Buy? - Defense World
Springworks Therapeutics Inc Stock (SWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):